1249 STATINS SLOW PROSTATE GROWTH: RESULTS FROM THE REDUCTION BY DUTASTERIDE OF CANCER EVENTS (REDUCE) TRIAL
Notice bibliographique
Résumé
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical and Hormonal Therapy1 Apr 20121249 STATINS SLOW PROSTATE GROWTH: RESULTS FROM THE REDUCTION BY DUTASTERIDE OF CANCER EVENTS (REDUCE) TRIAL Roberto Muller, Leah Gerber, Daniel Moreira, Gerald Andriole, J. Kellogg Parsons, Neil Fleshner, and Stephen Freedland Roberto MullerRoberto Muller Durham, NC More articles by this author , Leah GerberLeah Gerber Durham, NC More articles by this author , Daniel MoreiraDaniel Moreira New Hyde Park, NY More articles by this author , Gerald AndrioleGerald Andriole Saint Louis, MO More articles by this author , J. Kellogg ParsonsJ. Kellogg Parsons San Diego, CA More articles by this author , Neil FleshnerNeil Fleshner Toronto, Canada More articles by this author , and Stephen FreedlandStephen Freedland Durham, NC More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1567AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Statins are cholesterol-lowering agents with anti-inflammatory and apoptotic properties. We previously found starting a statins was associated with 4.1% reduced PSA levels within 1 year and, given PSA correlates with prostate volume (PV), we hypothesized statins may affect PV. Indeed, a study of 416 men with PV<30mL and PV measured serially by transrectal ultrasound (TRUS) over many years found statin use reduced the risk of a PV >30mL. However, a 6-month trial of atorvastatin vs. placebo showed no effect on PV. We tested if statins were associated with PV changes in REDUCE, a 4-year randomized trial of dutasteride vs. placebo for prostate cancer prevention wherein TRUS PV was obtained from mandated on-study biopsies regardless of PSA. METHODS Men were aged between 50-75 yrs, had a PSA between 2.5-10 ng/mL, a prior negative prostate biopsy, and a pre-study PV of <80cc. PV was obtained from TRUS at 2- and 4-year biopsies and compared to baseline. Of 8122 men in the efficacy population, after excluding PV after prostatic surgery, 6423 men (79.1%) had serial PV data, of which we excluded 330 (5.1%) due to missing data or extreme PV change from baseline. Statin use was assessed at baseline. We used multivariable linear regression to test if statin use was associated with PV changes at 2- and 4-years stratified by placebo and dutasteride arms. Models were adjusted for confounders. RESULTS Of 6093 men, 1032 used statins at baseline (16.9%). They were older (63.3 vs. 62.7 years, P=0.001) but had similar baseline PV (P=0.55) vs. non-statin users. At 2-years, after adjusting for multiple confounders, prostate growth was less for statin users in both the placebo (3.9% decrease in PV growth, P=0.02) and the dutasteride arms (5.0% decrease in PV growth, P<0.001). However, after adjusting for multiple confounders, statin use was not associated with PV growth from the 2- to 4-year time in either the placebo (0.0% change PV growth, P=0.52) and dutasteride arms (0.0% change in PV growth, P=0.64). CONCLUSIONS In men with an elevated PSA and a negative prostate biopsy, statin use was associated with a modest reduction in PV growth, which occurs within 2-years with no further reductions over the next 2 years. The degree of PV growth reduction (∼4%) is consistent with our prior results that statins reduce PSA levels by 4.1% suggesting the declines in PSA in our prior study may be due to reductions in PV. Further prospective studies are needed to confirm these findings as well as to understand the mechanisms by which statins reduce PV. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e505 Peer Review Report Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Roberto Muller Durham, NC More articles by this author Leah Gerber Durham, NC More articles by this author Daniel Moreira New Hyde Park, NY More articles by this author Gerald Andriole Saint Louis, MO More articles by this author J. Kellogg Parsons San Diego, CA More articles by this author Neil Fleshner Toronto, Canada More articles by this author Stephen Freedland Durham, NC More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,020 | 0,002 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».